THE RESULTS OF INTENSIVE INDUCTION CHEMOTHERAPY İN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA

Volume: 39 Number: 2 June 1, 2000
  • Murat Tombuloğlu
  • Seçkin Çağırgan
Ege Journal of Medicine Cover
Ege Journal of Medicine
PDF Download
EN TR

THE RESULTS OF INTENSIVE INDUCTION CHEMOTHERAPY İN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA

Abstract

In the last 15 years several studies have shovved that most of the patients with acute lymphoblastic leukemia can achieve complete remission by intensive induction chemotherapy. In this study we retrospectively investigated the results of the treatment of 19 adult patients with acute lymphoblastic leukemia treated by intensive induction chemotherapy. The results were compared with the 23 patients who were given less intensive induction chemotherapy during the same period. In the intensive chemotherapy group the remission rate was 84.2 %. After 61 months of follow-up, the median remission duration was 48 months and overall survival was 24 months. In control group, remission rate was 60.8 %, remission duration 6 months and total survival was 9 months. There was no early mortality detected due to intensive induction chemotherapy although ali the patients had febrile neutropenic attacks during the treatment period. In conclusion intensive induction chemotherapy car significantly increase the rate and duration of remission even though it does not have any effect on early mortality rates.

Keywords

Details

Primary Language

Turkish

Subjects

-

Journal Section

-

Authors

Murat Tombuloğlu

Seçkin Çağırgan

Publication Date

June 1, 2000

Submission Date

June 1, 2000

Acceptance Date

-

Published in Issue

Year 2000 Volume: 39 Number: 2

IZ

https://izlik.org/JA95ZZ32DU

Cite

RIS / Bibtex
Vancouver
1.Murat Tombuloğlu, Seçkin Çağırgan. ERİŞKİN AKUT LENFOBLASTİK LÖSEMİLİ OLGULARDA YOĞUN İNDÜKSİYON KEMOTERAPİSİ SONUÇLARI. EJM [Internet]. 2000 Jun. 1;39(2):113-5. Available from: https://izlik.org/JA95ZZ32DU

Ege Journal of Medicine enables the sharing of articles according to the Attribution-Non-Commercial-Share Alike 4.0 International (CC BY-NC-SA 4.0) license.